Загрузка...

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

BACKGROUND: Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotec...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ESMO Open
Главные авторы: Aoki, Masahiko, Shoji, Hirokazu, Nagashima, Kengo, Imazeki, Hiroshi, Miyamoto, Takahiro, Hirano, Hidekazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Higuchi, Kazuhide, Boku, Narikazu
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2019
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555603/
https://ncbi.nlm.nih.gov/pubmed/31231567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000488
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!